Proxy statement

Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders

Retrieved on: 
Tuesday, June 20, 2023

The adjourned Special Meeting will reconvene on Friday, June 23, 2023, at 1:00 p.m. (Eastern Time) virtually at https://meetnow.global/MVHUJSD.

Key Points: 
  • The adjourned Special Meeting will reconvene on Friday, June 23, 2023, at 1:00 p.m. (Eastern Time) virtually at https://meetnow.global/MVHUJSD.
  • The record date for the adjourned Special Meeting remains the same, May 30, 2023.
  • During this adjournment, the Company will continue to solicit votes from its stockholders regarding all proposals set forth in the Proxy Statement.
  • Proxies previously submitted will be voted at the adjourned Special Meeting, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.

Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting

Retrieved on: 
Tuesday, June 13, 2023

DEVON, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that it has adjourned its 2023 Annual Meeting of Stockholders (“Annual Meeting”) solely with respect to Proposal 2 set forth in its Definitive Proxy Statement (“Proxy Statement”) filed with the Securities and Exchange Commission on April 21, 2023. All other proposals on the Proxy Statement were approved by stockholders during the Annual Meeting held earlier today.

Key Points: 
  • All other proposals on the Proxy Statement were approved by stockholders during the Annual Meeting held earlier today.
  • The Company has adjourned the Annual Meeting with respect to Proposal 2 to provide its stockholders additional time to vote on the proposal.
  • The reconvened Annual Meeting will also be a “virtual” meeting of stockholders.
  • Vote at the virtual Annual Meeting by joining the meeting at https://web.lumiagm.com/236626312 (password: zyne2023) using the control number included on the proxy card.

Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders

Retrieved on: 
Thursday, May 25, 2023

ANN ARBOR, Mich., May 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) has been adjourned to allow additional time for stockholders to vote on the proposals set forth in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 13, 2023 (the “Proxy Statement”).

Key Points: 
  • ANN ARBOR, Mich., May 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) has been adjourned to allow additional time for stockholders to vote on the proposals set forth in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 13, 2023 (the “Proxy Statement”).
  • No changes have been made to the record date or the proposals to be brought before the Annual Meeting, which are presented in the Proxy Statement.
  • Accordingly, we have opted to reconvene our Annual Meeting on June 15, 2023 in order to provide stockholders with additional time to cast their votes.
  • Proxies previously submitted in respect of the 2023 Annual Meeting will be voted at the reconvened meeting unless properly revoked.

Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders

Retrieved on: 
Tuesday, May 23, 2023

The Company also announced today that the board of directors of the Company approved the implementation of the Reverse Stock Split immediately after the Meeting on the basis of 15 pre-Reverse Stock Split Common Shares for each one post-Reverse Stock Split Common Share.

Key Points: 
  • The Company also announced today that the board of directors of the Company approved the implementation of the Reverse Stock Split immediately after the Meeting on the basis of 15 pre-Reverse Stock Split Common Shares for each one post-Reverse Stock Split Common Share.
  • The Company will provide further information on the effectiveness of the Reverse Stock Split at a later date.
  • As a result of the Reverse Stock Split, every 15 Common Shares issued and outstanding will be automatically reclassified into one new Common Share.
  • Such holders do not need to take any additional actions to exchange their pre-Reverse Stock Split Common Shares for post-Reverse Stock Split Common Shares.

Beard Energy Transition Acquisition Corp. Announces Stockholder Approval of Proposals at Special Meeting

Retrieved on: 
Thursday, May 25, 2023

Beard Energy Transition Acquisition Corp. (NYSE: BRD) (“BRD” or “SPAC”), a publicly-traded special purpose acquisition company, today announced that its stockholders voted to approve all proposals presented at BRD’s special meeting of stockholders (the “Special Meeting”) held on May 25, 2023 in connection with extending the date by which BRD may consummate a business combination and the other matters described in BRD’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 1, 2023 (the “Proxy Statement”).

Key Points: 
  • Beard Energy Transition Acquisition Corp. (NYSE: BRD) (“BRD” or “SPAC”), a publicly-traded special purpose acquisition company, today announced that its stockholders voted to approve all proposals presented at BRD’s special meeting of stockholders (the “Special Meeting”) held on May 25, 2023 in connection with extending the date by which BRD may consummate a business combination and the other matters described in BRD’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 1, 2023 (the “Proxy Statement”).
  • Approximately 98.92% of the votes cast and 84.50% of the outstanding shares of common stock of BRD were in favor of approving the Extension Amendment Proposal (as defined in the Proxy Statement), and approximately 98.92% of the votes cast and 84.50% of the outstanding shares of common stock of BRD were in favor of approving the Trust Amendment Proposal (as defined in the Proxy Statement).
  • BRD plans to file the results of the Special Meeting, as tabulated by an independent inspector of elections, on a Form 8-K with the SEC within four business days (the “Special Meeting Results 8-K”).
  • Stockholders holding 15,872,896 shares of Class A common stock exercised their right to redeem such shares for a pro rata portion of the funds in BRD’s trust account (the “Trust Account”).

Mid-Southern Bancorp, Inc. Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “AGAINST” Stockholder Proposal Recommending the Engagement of an Investment Banking Firm

Retrieved on: 
Tuesday, May 16, 2023

We urge you to vote AGAINST the stockholder proposal by signing, dating and returning the proxy card for the Annual Meeting.

Key Points: 
  • We urge you to vote AGAINST the stockholder proposal by signing, dating and returning the proxy card for the Annual Meeting.
  • The Board of Directors believes that the stockholder proposal is unnecessary and not in the best interests of the Company or its stockholders.
  • In addition, the Proxy Statement, proxy card and 2022 Annual Report to Stockholders are available at http://www.viewproxy.com/MSVB/2023 .
  • Details concerning the nominees of the the Company’s Board of Directors for election at the Annual Meeting are also included in the Proxy Statement.

Leading Proxy Advisory Firms Support Blackwells’ Case for Board Change at Global Net Lease, Inc. and The Necessity Retail REIT, Inc.

Retrieved on: 
Wednesday, May 10, 2023

Glass Lewis’ recommendation follows Institutional Shareholder Services, Inc. (“ISS”) recommendation to withhold support from GNL and RTL’s incumbent director candidates.

Key Points: 
  • Glass Lewis’ recommendation follows Institutional Shareholder Services, Inc. (“ISS”) recommendation to withhold support from GNL and RTL’s incumbent director candidates.
  • This years’ ISS report follows reports from the last two years where ISS has repeatedly refused to endorse the incumbent nominees at GNL and RTL.
  • Jason Aintabi, Founder and Chief Investment Officer of Blackwells, commented:
    “We believe the time has come to say goodnight to the AR Global complex.
  • The years of abysmal results at each publicly listed entity under the millstone of AR Global, juxtaposed against the astronomical fees that AR Global continues to accumulate, is no longer tolerable.

Gogoro to Hold Annual General Meeting on May 30, 2023

Retrieved on: 
Wednesday, May 10, 2023

TAIPEI, Taiwan , May 10, 2023 /PRNewswire/ -- Gogoro Inc. (Nasdaq: GGR), a global technology leader in battery swapping ecosystems that enable sustainable mobility solutions for cities, today announced that it will hold its 2023 Annual General Meeting of Shareholders (the "AGM") at Building C, No.

Key Points: 
  • TAIPEI, Taiwan , May 10, 2023 /PRNewswire/ -- Gogoro Inc. (Nasdaq: GGR), a global technology leader in battery swapping ecosystems that enable sustainable mobility solutions for cities, today announced that it will hold its 2023 Annual General Meeting of Shareholders (the "AGM") at Building C, No.
  • 225, Sec.
  • 2, Chang'an E.
  • Rd., Songshan Dist., Taipei City, Taiwan 105, on the 30th day of May 2023 at 9:30 AM Taipei time.

Ovintiv Announces Results of Annual Meeting

Retrieved on: 
Monday, May 8, 2023

DENVER, May 8, 2023 /PRNewswire/ - Ovintiv Inc. (NYSE: OVV) (TSX: OVV) (the "Company") today announced that the following matters, as further described in the Company's Proxy Statement filed on March 23, 2023 (the "Proxy Statement"), were voted upon at its 2023 Annual Meeting of Shareholders held on May 3, 2023.

Key Points: 
  • DENVER, May 8, 2023 /PRNewswire/ - Ovintiv Inc. (NYSE: OVV) (TSX: OVV) (the "Company") today announced that the following matters, as further described in the Company's Proxy Statement filed on March 23, 2023 (the "Proxy Statement"), were voted upon at its 2023 Annual Meeting of Shareholders held on May 3, 2023.
  • Each director nominee listed in the Proxy Statement was elected as a director of the Company.
  • The results of the vote by ballot were as follows:

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023

Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.

Key Points: 
  • Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.
  • Revenue: Total revenue was $12.1 million for the first quarter of 2023, compared to $5.3 million for the first quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $46.7 million for the first quarter of 2023, compared to $32.4 million for the first quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $22.9 million for the first quarter of 2023, compared to $21.1 million for the first quarter of 2022.